The Swiss company is a pioneer in the development of live-cell imaging, and digital analytical solutions
The swiss leading live-cell imaging and analysis company, announces that it has successfully completed the initial closing of US $20 million in the Series C-1 equity financing round of investment, led by a US-based and NASDAQ listed life science investor, and Taiwania Capital, the leading life science venture capital company based in Taiwan.
This equity round of investment is also supported by investments from existing investors, including Swisscom Ventures, along with other partners. Nanolive is working closely with investors to secure a second close within ninety days. Nanolive’
s cutting-edge label-free microscope devices and state-of-the-art digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy. Being able to screen thousands of living cells in 3D, without damaging them promises to radically advance how scientists study living cells.
Combining sub-cellular resolution with unique AI-assisted digital assays provides researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow. “Life Sciences are undergoing a fundamental transformation, and Nanolive is at the heart of it,” says Dr. Yann Cotte, Nanolive’s CEO and Co-Founder. “We are honored to receive an investment from such an impressive group of investors who are excited to support us in our goal to transform the discovery and development of therapeutics. With this fundraising, we believe Nanoliveis well-positioned to drive significant growth of our Digital Assay solutions and is at the leading edge of this global bioeconomy gold rush. We are selling the best picks and shovels for live-cell solutions.”
“We are thrilled to be part of a Swiss-based innovative company that will revolutionize the drug discovery process,” said Michael L. Huang, Managing Partner of Taiwania Capital. “With this funding, Nanolive is well-positioned to provide crucial tools and solutions to pharmaceutical and biotech companies and research institutes for developing better therapies that would save millions of patient lives”.
The Swiss company is a pioneer in the development and commercialization of innovative label-free, non-invasive live-cell imaging, and state-of-the-art digital analytical solutions. Nanolive’s breakthrough live-cell imaging and analysis platforms . The solutions combine screening, imaging, and analysis. The tools radically accelerate innovation in growth industries such as drug discovery and cell therapy. They provide novel biological insights on the mechanisms of cancer and neurodegenerative diseases.